Putting Biogen's Aduhelm crisis behind him, Al Sandrock grabs CEO role at gene therapy player to lead turnaround mission
Al Sandrock’s re-entry back to biotech comes just as abruptly as his last exit.
The Biogen vet — who retired last November as R&D chief after steering the Alzheimer’s drug aducanumab (now Aduhelm) straight into a storm of controversy surrounding its approval and rollout — has taken Voyager Therapeutics’ offer to be its CEO.
Voyager was Sandrock’s first port of call after he left Biogen. He joined not just the board but a newly formed three-person executive team tasked with guiding the gene therapy company as it tries to rebrand itself after two troubled years. He’s since amassed a dozen of other board seats.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
